

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICATION NUMBER:	<b>10/559,401</b>
FILING DATE:	<b>9/11/2008</b>
FIRST NAMED INVENTOR:	<b>C. Frank Bennett</b>
ART UNIT:	<b>1635</b>
EXAMINER NAME:	<b>Jane J. Zara</b>
CONFIRMATION NUMBER:	<b>5614</b>
ATTORNEY DOCKET NUMBER:	<b>ISPH-0852USA</b>
TITLE:	<b>OLIGONUCLEOTIDE MODULATION OF CELL ADHESION</b>

---

MAIL STOP AMENDMENT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
Under 37 C.F.R. §§ 1.56 and 1.97-98

Dear Examiner Zara:

Pursuant to the provisions of 37 C.F. R. §§ 1.56 and 1.97-98, enclosed herewith is PTO Form PTO/SB/08A and PTO/SB/08B listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.


A CD-ROM was purportedly contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on March 14, 2002. The CD-ROM is purported to contain a document by Chin entitled "On the Preparation and Utilization of Isolated and Purified Oligonucleotides." The document has been included on the form PTO/SB/08A and a paper copy is enclosed herewith. The CD-ROM is also purported to contain a listing of "all sequences of 8 to 12 nucleotides that have between 40 and 60 percent G+C content and are free of homopolymeric runs of 4 or more bases and directly or inversely repeated regions of 4 or more bases" a paper copy of which is too voluminous to submit herewith. Applicant's submission of the foregoing information shall not be construed as an admission that the purported CD-ROM contains that which it is purported to contain nor shall it be construed as an admission that the purported CD-ROM is a publication.

This Information Disclosure Statement is being filed after the mailing date of the first office action on the merits, but before the mailing date of either: (1) a final action under 37 C.F.R. § 1.113; or (2) an action that otherwise closes prosecution in the application. Attached hereto is the fee set forth under 37 C.F.R. § 1.17(p) for submission of this Information Disclosure Statement under 37 C.F.R. § 1.97(c).

The Commissioner is hereby authorized to charge any fee required or credit any overpayment to Deposit Account No 500252 referencing case number ISPH-0852USA.

Consideration of the listed references is respectfully requested.

Respectfully submitted,

  
Teresa Y. Liang, Ph.D.  
Registration No.: 51,946  
Isis Pharmaceuticals, Inc.  
1896 Rutherford Road  
Carlsbad, CA 92008

Dated: Dec 27, 2010